Shopping Cart
- Remove All
Your shopping cart is currently empty
Anti-PD-L1 Antibody (2T937) is a Rabbit antibody targeting PD-L1. Anti-PD-L1 Antibody (2T937) can be used in FCM.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 100 μL | $293 | 7-10 days |
| Description | Anti-PD-L1 Antibody (2T937) is a Rabbit antibody targeting PD-L1. Anti-PD-L1 Antibody (2T937) can be used in FCM. |
| Synonyms | Pdl1, Pdcd1lg1, Pdcd1l1, CD274 molecule, B7h1, A530045L16Rik |
| Ig Type | Rabbit IgG |
| Clone | 2T937 |
| Reactivity | Mouse |
| Specificity | Mouse PD-L1/B7-H1 |
| Verified Activity | Flow cytometric analysis of CD274 expression on spleen lymphocytes. BALB/c splenocytes were stained with Mouse CD274 Monoclonal Ab, then a FITC-conjugated second step antibody. The histogram were derived from the gated events based on light scattering characteristics of lymphocytes. |
| Application | |
| Recommended Dose | FCM: 1:25-1:100 |
| Antibody Type | Monoclonal |
| Host Species | Rabbit |
| Construction | This antibody was obtained from a rabbit immunized with purified, recombinant Mouse PD-L1 / B7-H1 / CD274 (rM PD-L1 / B7-H1 / CD274; TMPY-01155; NP_068693.1; Met 1-Thr 238). |
| Purification | Protein A |
| Appearance | Liquid |
| Formulation | 0.2 μm filtered solution in PBS |
| Research Background | Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Blockade: Blocking AntibodiImmune Checkpoint Blockade: PD-L1 / B7-H1 / CImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: ICC AntibodiesImmune Checkpoint Detection: IHC AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyPD-L1 / B7-H1 / CD274 Immune Checkpoint ProteTargeted Therapy |
| Conjucates | Unconjugated |
| Immunogen | Recombinant Protein: Mouse PD-L1 / B7-H1 / CD274 protein (TMPY-01155) |
| Antigen Species | Mouse |
| Biology Area | Cancer Drug Targets |
| Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
| Transport | Shipping with blue ice. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.